Fundamental Analysis of MADRIGAL PHARMACEUTICALS INC(NASDAQ:MDGL) stock

Fundamental Rating

Taking everything into account, MDGL scores 2 out of 10 in our fundamental rating. MDGL was compared to 587 industry peers in the Biotechnology industry. MDGL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MDGL has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

MDGL had negative earnings in the past year.

MDGL had a negative operating cash flow in the past year.

In the past 5 years MDGL always reported negative net income.

In the past 5 years MDGL always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -58.32%, MDGL is in line with its industry, outperforming 42.39% of the companies in the same industry.

MDGL has a Return On Equity (-92.17%) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-58.32%
ROE	-92.17%
ROIC	N/A

ROA(3y)-76.09%

ROA(5y)-63.54%

ROE(3y)-121.71%

ROE(5y)-93.9%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

MDGL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MDGL has more shares outstanding than it did 1 year ago.

MDGL has more shares outstanding than it did 5 years ago.

MDGL has a worse debt/assets ratio than last year.

2.2 Solvency

MDGL has an Altman-Z score of 7.38. This indicates that MDGL is financially healthy and has little risk of bankruptcy at the moment.

MDGL has a better Altman-Z score (7.38) than 83.08% of its industry peers.

A Debt/Equity ratio of 0.28 indicates that MDGL is not too dependend on debt financing.

MDGL has a Debt to Equity ratio of 0.28. This is in the lower half of the industry: MDGL underperforms 69.74% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.28
Debt/FCF	N/A
Altman-Z	7.38

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 5.38 indicates that MDGL has no problem at all paying its short term obligations.

MDGL has a Current ratio (5.38) which is in line with its industry peers.

MDGL has a Quick Ratio of 5.38. This indicates that MDGL is financially healthy and has no problem in meeting its short term obligations.

With a Quick ratio value of 5.38, MDGL perfoms like the industry average, outperforming 57.78% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	5.38
Quick Ratio	5.38

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for MDGL have decreased strongly by -15.73% in the last year.

EPS 1Y (TTM)-15.73%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-14.06%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

Based on estimates for the next years, MDGL will show a very strong growth in Earnings Per Share. The EPS will grow by 38.23% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-20.1%

EPS Next 2Y12.26%

EPS Next 3Y32.68%

EPS Next 5Y38.23%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

MDGL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year MDGL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as MDGL's earnings are expected to grow with 32.68% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y12.26%

EPS Next 3Y32.68%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for MDGL!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MADRIGAL PHARMACEUTICALS INC

NASDAQ:MDGL (5/9/2024, 7:04:45 PM)

After market: 206.92 0 (0%)

206.92

-1.12 (-0.54%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap4.40B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-58.32%
ROE	-92.17%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.28
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	5.38
Quick Ratio	5.38
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-15.73%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-20.1%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

MADRIGAL PHARMACEUTICALS INC (MDGL)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens